Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: The role of positron emission tomography/computed tomography - based treatment planning

Clinical Lung Cancer

Volumn 9, Issue 4, 2008, Pages 217-221

  Coon, Devin ^a   Gokhale, Abhay S ^a   Burton, Steven A ^a,c   Heron, Dwight E ^a   Ozhasoglu, Cihat ^a   Christie, Neil ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Cyberknife; Hypofractionated; Standardized uptake value; Synchrony

Indexed keywords

FLUORODEOXYGLUCOSE;

ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEVICE; DISEASE COURSE; FOLLOW UP; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; RADIATION DOSE FRACTIONATION; STEREOTACTIC PROCEDURE; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; WHOLE BODY RADIATION;

EID: 49249133535     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.032     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Smythe WR. Treatment of stage I non-small cell lung carcinoma. Chest 2003; 123:181S-7S.
3. Loran DB, Zwischenberger JB. Thoracic surgery in the elderly. J Am Coll Surg 2004; 199:773-84.
4. Sibley GS. Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma: smaller volumes and higher doses - a review. Cancer 1998; 82:433-8.
5. Jeremic B, Classen J, Bamberg M. Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 54:119-30.
6. Pennathur A, Luketich JD, Burton S, et al. Stereotactic radiosurgery for rhe treatment of lung neoplasm: initial experience. Ann Thorac Surg 2007; 83:1820-4; discussion 1824-5.
7. Hoopes DJ, Tann M, Flercher JW, et al. FDG-PET and srereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 2007; 56:229-34.
8. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004; 101:1623-31.
9. Song DY, Kavanagh BD, Benedict SH, et al. Stereotactic body radiarion therapy. Rationale, techniques, applications, and optimization. Oncology (Williston Park) 2004; 18:1419-30; discussion 1430, 1432, 1435-6.
10. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of posirron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003; 139:879-92.
11. Heron DE, Smith RP, Andrade RS. Advances in image-guided radiation therapy-the role of PET-CT. Med Dosim 2006; 31:3-11.
12. Yeung HW, Schoder H, Smith A, et al. Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patienrs. Mol Imaging Biol 2005; 7:229-35.
13. Herrera LJ, Fernando HC, Perry Y, et al. Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J Thorac Cardiovasc Surg 2003; 125:929-37.
14. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005; 63:1427-31.
15. Seppenwoolde Y, Shirato H, Kitamura K, et al. Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. Int J Radiat Oncol Biol Phys 2002; 53:822-34.
16. Slotman BJ, Lagerwaard FJ, Senan S. 4D imaging for target definition in stereotactic radiotherapy for lung cancer. Acta Oncol 2006; 45:966-72.
17. Ozhasoglu C, Christie N, Luketich J. Target Immobilization with natural breathholding: possible applications to IMRT and body radiosurgery [abstract]. Medical Physics 2003; 301:338.
18. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003; 124:1946-955.
19. Schweikard A, Shiomi H, Adler J. Respiration tracking in radiosurgery. Med Phys 2004; 31:2738-41.
20. Casamassima F, Cavedon C, Francescon P, et al. Use of motion tracking in stereotactic body radiotherapy: evaluation of uncertainty in off-target dose distribution and optimization strategies. Acta Oncol 2006; 45:943-7.
21. Vansreenkiste JF, Stroobanrs SG. Positron emission tomography in the management of non-small cell lung cancer. Hematol Oncol Clin North Am 2004; 18:269-88.
22. Vansteenkisre JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17:3201-6.
23. Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by posirron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23:1136-43.
24. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004; 22:3255-60.
25. Pillot G, Siegel BA, Govindan R. Prognosric value of fluorodeoxyglucose positron emission romography in non-small cell lung cancer: a review. J Thorac Oncol 2006; 1:152-9.